New pill shows promise for tough leukemias in early trial
NCT ID NCT06052813
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an oral drug called BN104 in adults and adolescents with acute leukemia that has come back or not responded to treatment. The drug targets specific genetic changes (KMT2A rearrangement or NPM1 mutation) that drive the cancer. The trial aims to check safety, how the body processes the drug, and whether it can reduce leukemia cells in the bone marrow.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BN104 (a menin inhibitor taken orally)
- What this could lead to
- If successful, this could provide a new treatment option for patients with hard-to-treat acute leukemias that have specific genetic mutations.
- What could go wrong
- This is an early-phase trial with only 66 participants, so results may not apply broadly. The drug may cause side effects or fail to control the leukemia long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LEUKAEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, 215006, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can donor immune cells tame stem cell transplant risks?
- Can targeted drug cocktails erase hidden leukemia cells?